Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

  Email address:
   

Shanghai's Harbour BioMed Raises $50 Million; Acquires Discovery Company

publication date: Dec 20, 2016
Harbour BioMed, a Shanghai startup, raised an initial $50 million from two China investors, Advantech Capital and Legend Capital, and then acquired Harbour Antibodies BV, a Dutch company with two proprietary transgenic mouse platforms. Harbour BioMed's headquarters and R&D will be in Shanghai, its business operations in Cambridge, MA and its antibody platform in Rotterdam. The company will expand its Boston presence with a drug discovery innovation center. The previous Harbour owners received cash plus equity in Harbour BioMed, though no specific details were disclosed. More details....

Share this with colleagues:  


This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes


Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital